Journal
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 92, Issue 2, Pages 168-171Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2018.05.018
Keywords
Apramycin; Staphylococcus aureus; Activity spectrum; Repurposing; Antibiotic; Natural product; Synergy; Aminoglycoside; Gentamicin
Categories
Funding
- Chief Academic Officer's Pilot Award from Beth Israel Deaconess Medical Center
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [K08AI132716, T32AI007061, F32 AI124590]
Ask authors/readers for more resources
We evaluated the in vitro activity of apramycin against clinical strains of vancomycin-intermediate and methicillin-resistant and -susceptible Staphylococcus aureus. Apramycin demonstrated an MIC50/MIC90 of 8/16 mu g/mL. No strains had an MIC above the epidemiological cutoff value of 32 mu g/mL, suggesting apramycin resistance mechanisms are rare in this strain population. The mounting evidence for broad-spectrum in vitro activity of apramycin against S. aureus and other bacterial species suggests that further exploration of apramycin or derivatives as repurposed human therapeutics is warranted. (C) 2018 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available